Replies to post #77843 on Biotech Values

[rkrw]

Have any generic companies filed yet?

[genisi]

MDCO believes that most companies will find it difficult to make bivalirudin in necessary ton quantity. Perhaps the facts that Hatch-Waxman exclusivity expired Nov 2008 and no paragraph IV filings have occurred, imply that generics might have a high manufacturing hurdle.

[DewDiligence]

MDCO addendum: SG&A during 1Q09 was ~55% of product sales! This has to be one of the highest proportions ever for a company with a $400M product.